Anergix, LLC is developing a peptide delivery treatment for multiple sclerosis (MS) and other autoimmune diseases.  Our technology is antigen specific in contrast to the existing disease modifying therapies (DMTs) that are broadly immunomodulatory and have numerous side effects.

In MS, our lead program, the strategy is to induce immune tolerance to a segment of myelin basic protein (MBP) one of the known targets of the autoimmune response against the myelin proteins surrounding nerve cells.